MCID: SML019
MIFTS: 55

Smallpox

Categories: Infectious diseases, Mental diseases, Rare diseases, Skin diseases

Aliases & Classifications for Smallpox

MalaCards integrated aliases for Smallpox:

Name: Smallpox 12 74 20 54 42 3 44 15 71 32
Ordinary Smallpox 12
Variola 20

Classifications:



External Ids:

Disease Ontology 12 DOID:8736
ICD9CM 34 050
MeSH 44 D012899
NCIt 50 C35027
SNOMED-CT 67 266193008
ICD10 32 B03
UMLS 71 C0037354

Summaries for Smallpox

MedlinePlus : 42 Smallpox is a disease caused by the Variola major virus. Some experts say that over the centuries it has killed more people than all other infectious diseases combined. Worldwide vaccination stopped the spread of smallpox three decades ago. The last case was reported in 1977. Two research labs still keep small amounts of the virus. Experts fear bioterrorists could use the virus to spread disease. Smallpox spreads very easily from person to person. Symptoms are flu-like. They include High fever Fatigue Headache Backache A rash with flat red sores There is no treatment. Fluids and medicines for pain or fever can help control symptoms. Most people recover, but some can die. Those who do recover may have severe scars. The U.S. stopped routine smallpox vaccinations in 1972. Military and other high-risk groups continue to get the vaccine. The U.S. has increased its supply of the vaccine in recent years. The vaccine makes some people sick, so doctors save it for those at highest risk of disease.

MalaCards based summary : Smallpox, also known as ordinary smallpox, is related to vaccinia and plague, and has symptoms including fever, pruritus and exanthema. An important gene associated with Smallpox is IL4 (Interleukin 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Sevelamer and Calcium acetate have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Variola virus, which is transmitted by droplets from oral, nasal or pharyngeal mucosa, transmitted by contact with the body fluids, or transmitted by fomites. The infection results in formation of lesions, first on the face, hands and forearms and later on the trunk.

CDC : 3 Before smallpox was eradicated, it was a serious infectious disease caused by the variola virus. It was contagious-meaning, it spread from one person to another. People who had smallpox had a fever and a distinctive, progressive skin rash. Most people with smallpox recovered, but about 3 out of every 10 people with the disease died. Many smallpox survivors have permanent scars over large areas of their body, especially their faces. Some are left blind. Thanks to the success of vaccination, smallpox was eradicated, and no cases of naturally occurring smallpox have happened since 1977. The last natural outbreak of smallpox in the United States occurred in 1949.

Wikipedia : 74 Smallpox was an infectious disease caused by one of two virus variants, Variola major and Variola minor.... more...

Related Diseases for Smallpox

Diseases related to Smallpox via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 597)
# Related Disease Score Top Affiliating Genes
1 vaccinia 32.2 TNF IL2 ICAM1 GZMB CSF2
2 plague 31.5 TNF IL2 IL1B
3 chickenpox 31.4 TNF IL4 IL2 IFNG
4 poliomyelitis 31.3 TNF IL4 IFNG ICAM1
5 encephalitis 31.2 TNF ITIH4 IL1B CXCL9
6 measles 31.2 TNF IL2 IL1B IFNG
7 typhoid fever 31.1 TNF IL1B IFNG
8 pericarditis 31.0 TNF IL1B IFNG
9 tetanus 31.0 TNF IL4 IL2 IL1B IFNG
10 diphtheria 30.9 TNF IL4 IL2 IL1B IFNG CSF2
11 exanthem 30.9 TNF IL2 IL1B IL18 IFNG CSF3
12 myocarditis 30.9 TNF IL4 IL2 IL1B IL18 IFNG
13 herpes zoster 30.8 TNF IL2 IFNG
14 purpura 30.8 TNF IL4 IL1B IFNG
15 disease by infectious agent 30.8 TNF ITIH4 IL4 IL2 IL1B IL18
16 severe acute respiratory syndrome 30.7 TNF IL1B IFNG CXCL9
17 erythema multiforme 30.6 TNF IL4 IL2 IFNG ICAM1 GZMB
18 dermatitis 30.4 TNF IL4 IL2 IL1B IL18 IFNG
19 severe combined immunodeficiency 30.4 IL4 IL2 IL18R1 IFNG CSF3 CSF2
20 cellulitis 30.4 TNF CSF3 CSF2
21 rhinitis 30.4 TNF IL4 IFNG ICAM1
22 stevens-johnson syndrome/toxic epidermal necrolysis 30.4 IL2 IFNG CXCR3
23 optic neuritis 30.4 TNF IL1B CXCR3
24 bacterial sepsis 30.3 TNF IL1B IL18
25 allergic rhinitis 30.3 IL4 IL18 IFNG ICAM1 CSF2
26 rubella 30.3 TNF IL4 IL2 IL1B IL18R1 IFNG
27 mumps 30.3 TNF IRF1 IL2 IL1B IL12RB2 IFNG
28 q fever 30.3 TNF IL4 IL1B IFNG
29 dermatitis, atopic 30.3 TNF IL4 IL2 IL1B IL18 IFNG
30 osteomyelitis 30.2 TNF IL4 IL1B IFNG CSF3
31 conjunctivitis 30.2 TNF IL4 IL2 IFNG ICAM1 CXCL9
32 brucellosis 30.2 TNF IL4 IL2 IL18 IFNG
33 neuritis 30.2 TNF IL4 IL1B IFNG CXCR3 CXCL9
34 toxic shock syndrome 30.2 TNF IL4 IL2 IL1B IFNG
35 central nervous system disease 30.2 TNF IL1B IFNG CXCR3
36 pulmonary tuberculosis 30.1 TNF IL4 IL2 IL18 IFNG
37 amelia, posterior, with pelvic and pulmonary hypoplasia syndrome 30.1 IL18BP IL18
38 leprosy 3 30.1 TNF IL4 IL2 IL1B IL12RB2 IFNG
39 acquired immunodeficiency syndrome 30.1 TNF ITIH4 IL2 IL1B IFNG ICAM1
40 stomatitis 30.1 TNF IL4 IL2 IL1B IFNG CSF3
41 schistosomiasis 30.1 TNF IL4 IL2 IFNG
42 hepatitis a 30.1 TNF IL4 IL1B IFNG
43 dilated cardiomyopathy 30.1 TNF IL4 IL2 IL1B IFNG ICAM1
44 arthritis 30.1 TNF IL4 IL1B IL18 IFNG ICAM1
45 toxoplasmosis 30.1 TNF IL4 IL1B IFNG
46 combined immunodeficiency 30.1 TNF IL4 IL2 IFNG ICAM1 CSF3
47 pleurisy 30.0 TNF IL2 IFNG ICAM1
48 rheumatic fever 30.0 TNF IL2 IFNG ICAM1
49 pyoderma 30.0 TNF IL1B CSF3
50 nervous system disease 30.0 TNF IL4 IL2 IL1B IFNG CXCR3

Graphical network of the top 20 diseases related to Smallpox:



Diseases related to Smallpox

Symptoms & Phenotypes for Smallpox

UMLS symptoms related to Smallpox:


fever, pruritus, exanthema

GenomeRNAi Phenotypes related to Smallpox according to GeneCards Suite gene sharing:

26 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.07 CSF3
2 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.07 IL18
3 Increased shRNA abundance (Z-score > 2) GR00366-A-148 10.07 CSF3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.07 IL18
5 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.07 IRF1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-160 10.07 IRF1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.07 IL18
8 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.07 MTHFR
9 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.07 IRF1 MTHFR
10 Increased shRNA abundance (Z-score > 2) GR00366-A-182 10.07 IL18
11 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.07 IRF1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-204 10.07 CSF3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.07 MTHFR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-27 10.07 IRF1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.07 IRF1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.07 IL18
17 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.07 IRF1 MTHFR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10.07 IL18
19 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.07 IRF1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-6 10.07 IL18 MTHFR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.07 MTHFR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.07 CSF3 IRF1
23 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 GZMA GZMB IL18 IL1B TNF
24 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 GZMA GZMB ICAM1 IL18 IL1B IL2
25 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.44 ICAM1

MGI Mouse Phenotypes related to Smallpox:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 CSF2 CSF3 CXCR3 GZMA ICAM1 IFNG
2 homeostasis/metabolism MP:0005376 10.2 CSF2 CXCR3 ICAM1 IFNG IL12RB2 IL18
3 immune system MP:0005387 10.13 CSF2 CSF3 CXCR3 GZMA ICAM1 IFNG
4 endocrine/exocrine gland MP:0005379 10.1 CSF2 ICAM1 IFNG IL12RB2 IL18BP IL2
5 integument MP:0010771 9.85 CSF2 CSF3 ICAM1 IFNG IL18 IL1B
6 liver/biliary system MP:0005370 9.56 IFNG IL12RB2 IL18BP IL2 IL4 ITIH4
7 neoplasm MP:0002006 9.36 CSF2 CXCR3 GZMA ICAM1 IFNG IL12RB2

Drugs & Therapeutics for Smallpox

Drugs for Smallpox (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevelamer Approved Phase 4 52757-95-6
2
Calcium acetate Approved, Investigational Phase 4 62-54-4
3 Immunologic Factors Phase 4
4 gamma-Globulins Phase 4
5 Immunoglobulins Phase 4
6 Antibodies Phase 4
7 Vaccines Phase 4
8 Immunoglobulins, Intravenous Phase 4
9 Rho(D) Immune Globulin Phase 4
10 Antiviral Agents Phase 4
11 Chelating Agents Phase 4
12 Calcium, Dietary Phase 4
13
Calcium Nutraceutical Phase 4 7440-70-2 271
14 Iron-Dextran Complex Phase 3
15
Phenol Approved, Experimental Phase 2 108-95-2 996
16
BCG vaccine Approved, Investigational Phase 1, Phase 2
17 Pharmaceutical Solutions Phase 1
18 interferons Phase 1
19 Poly ICLC Phase 1

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 A Post Marketing Study of the Safety, Tolerability, and Pharmacokinetics of TPOXX In Adult Subjects Weighing More Than 120 KG Completed NCT04392739 Phase 4 Tpoxx
2 Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Recruiting NCT02443623 Phase 4
3 A Post-Marketing Open-Label, 5 Period Crossover, Drug-Drug Interaction Study of Orally Adminstered TPOXX When Co-administered With 4 Different Phosphate Binders in Healthy Subjects Not yet recruiting NCT04485039 Phase 4 TPOXX
4 An Expanded Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti Orthopoxvirus Compound Tecovirimat When Administered Orally for 14 Days in Subjects Completed NCT02474589 Phase 3 tecovirimat
5 A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects Completed NCT01913353 Phase 3
6 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
7 A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects Completed NCT01144637 Phase 3
8 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
9 A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT03699124 Phase 3
10 Randomized, Double Blind, a Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300 in Healthy Volunteers Completed NCT00607243 Phase 2, Phase 3
11 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Completed NCT01158157 Phase 3
12 An Open-Label Prospective Cohort Study of IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Active, not recruiting NCT02977715 Phase 3
13 A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers Unknown status NCT00103584 Phase 1, Phase 2
14 Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
15 ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax® Immunization to Assess Effects of MVA Vaccination on Dryvax® Takes Completed NCT00133575 Phase 1, Phase 2
16 Phase II, Double-blind, Randomised, Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects Completed NCT00189956 Phase 2
17 The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination Completed NCT00053482 Phase 2
18 Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Study Assessing Safety, Tolerability, Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara Smallpox Vaccine in Adults With and Without Previous Smallpox Vaccination Completed NCT00466245 Phase 2 MVA Smallpox vaccine;Placebo
19 A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination Completed NCT00189904 Phase 1, Phase 2
20 The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Completed NCT00053495 Phase 2
21 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection Completed NCT02038881 Phase 2
22 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis Completed NCT00316602 Phase 2
23 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl. Completed NCT00316589 Phase 2
24 A Partially Randomized, Partially Double-blind, Placebo-controlled Phase II Non-inferiority Study to Evaluate Immunogenicity and Safety of One and Two Doses of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-55 Year Old Healthy Subjects Completed NCT00316524 Phase 2
25 A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults Completed NCT00038987 Phase 1, Phase 2
26 Take Evaluation and Safety of Smallpox Vaccine (LISTER Strain) in Naïve Healthy Adults. Completed NCT00258947 Phase 2
27 A Comparison of Dressing Preparations for Smallpox Vaccination Sites With a Focus Upon the Risk of Secondary Transmission of Vaccinia Virus Completed NCT00063856 Phase 1, Phase 2
28 A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00050505 Phase 2
29 A Multicenter, Double-Blind, Randomized Dose-Response Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults Completed NCT00026611 Phase 2
30 A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults. Completed NCT00050518 Phase 2
31 Evaluation of IMVAMUNE® Smallpox Vaccine With Respect to Safety and Optimization of Immune Responses by Different Vaccination Regimens in Vaccinia-Naïve Adults Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
32 A Double Blind, Randomized Dose Response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00032708 Phase 2
33 A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
34 A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
35 A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of IMVAMUNE® Using Three Immunization Schedules and Two Modes of Delivery Completed NCT01827371 Phase 2
36 An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees Completed NCT00686582 Phase 2
37 Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals Completed NCT00914732 Phase 2
38 Open Label, Dose Escalation and Age De-escalation for ChAdOx1 85A in Ugandan Adults and Adolescents, Followed by a Phase IIa Randomised, Open-label Trial Among Adolescents Comparing ChAdOx1 85A Prime Followed by MVA 85A Boost Versus BCG Re-vaccination. Recruiting NCT03681860 Phase 1, Phase 2
39 MVA-BN Imvamune Smallpox Vaccine Virus for Treatment of Basal Cell Carcinoma, Squamous Cell Carcinomas Recruiting NCT04410874 Phase 1, Phase 2
40 The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM1000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination A Phase 2, Randomized, Double-Blind, Dose-Response Study Terminated NCT00053508 Phase 2
41 MVA-BN (IMVAMUNE®) Immunization in Persons Who Have Undergone Prior Hematopoietic Stem Cell Transplant (HSCT): A Phase I, Placebo-Controlled Study of the Safety, Reactogenicity and Immunogenicity of MVA Immunization Completed NCT00565929 Phase 1 Placebo
42 The Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine, in Adults Without Previous Smallpox Vaccination Completed NCT00079820 Phase 1
43 A Phase I, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA 720 Adjuvant in 18-45 Year Old Healthy Adults Completed NCT02743455 Phase 1 ISA-720
44 Evaluation of Human Immune Response to Smallpox Vaccine (Vaccinia Virus) Completed NCT00068198 Phase 1
45 A Phase 1 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation (Take Rate) of a Cell-Cultured Smallpox Vaccine (CCSV) Compared to a Calf Lymph Vaccine (Dryvax®) Completed NCT00042094 Phase 1
46 Phase I Study to Evaluate Take Rate, Immunogenicity and Safety of Bavarian Nordic's Smallpox Vaccine Elstree-BN Administered to Healthy Vaccinia-Naive Subjects in the Age of 18-32 Years Completed NCT00189969 Phase 1
47 An Open-label, Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders Completed NCT00189917 Phase 1
48 A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers Completed NCT00002261 Phase 1
49 A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of MVA-BN in a Dose Response Regimen Followed by Administration of Dryvax in Healthy Adult Volunteers Completed NCT00082446 Phase 1
50 Randomized, Double Blind, Placebo Control Study to Evaluate the Safety and Immunogenicity of CJ-50300 in Healthy Volunteers : Phase I Completed NCT00336635 Phase 1

Search NIH Clinical Center for Smallpox

Cochrane evidence based reviews: smallpox

Genetic Tests for Smallpox

Anatomical Context for Smallpox

MalaCards organs/tissues related to Smallpox:

40
Skin, T Cells, Kidney, Eye, Bone Marrow, Breast, B Cells

Publications for Smallpox

Articles related to Smallpox:

(show top 50) (show all 7709)
# Title Authors PMID Year
1
Patterns of smallpox mortality in London, England, over three centuries. 61 42
33347440 2020
2
Fatal Infectious Epidemics in Iran in the Last Two Centuries; What Lessons Can We Learn from Preceding Outbreaks? A Brief Historical Review. 42 61
32894975 2020
3
Smallpox and other viruses plagued humans much earlier than suspected. 61 42
32704107 2020
4
Structural basis for antagonism of human interleukin 18 by poxvirus interleukin 18-binding protein. 61 54
19104048 2008
5
Yaba monkey tumor virus encodes a functional inhibitor of interleukin-18. 61 54
17959666 2008
6
Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus. 61 54
17141855 2007
7
Variola virus IL-18 binding protein interacts with three human IL-18 residues that are part of a binding site for human IL-18 receptor alpha subunit. 54 61
16979683 2007
8
Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design. 54 61
17062140 2006
9
Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus. 54 61
16185891 2005
10
Evolutionary history of orthopoxvirus proteins similar to human complement regulators. 54 61
16023794 2005
11
Identification of residues in an orthopoxvirus interleukin-18 binding protein involved in ligand binding and species specificity. 54 61
15193916 2004
12
Identification of the canarypox virus thymidine kinase gene and insertion of foreign genes. 54 61
10191193 1999
13
Offline: The lessons of smallpox eradication for COVID-19. 61
33341128 2021
14
Friedelin exhibits antidiabetic effect in diabetic rats via modulation of glucose metabolism in liver and muscle. 61
33271243 2021
15
Vaccinia virus-based vector against infectious diseases and tumors. 61
33606578 2021
16
COVID-19, varying genetic resistance to viral disease and immune tolerance checkpoints. 61
33113212 2021
17
(+)-Camphor and (-)-borneol derivatives as potential anti-orthopoxvirus agents. 61
33605479 2021
18
A critical assessment of proposed outbreaks of plague and other epidemic diseases in Ancient Egypt. 61
33227516 2021
19
Recurrent Erythema Nodosum Leprosum Associated With Mycobacterium Indicus Pranii Vaccine In A Case Of Leprosy: A Rare paradox. 61
33587765 2021
20
Protection against severe infectious disease in the past. 61
33573529 2021
21
Live Vaccinia Virus-Coated Microneedle Array Patches for Smallpox Vaccination and Stockpiling. 61
33546332 2021
22
Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model. 61
33536322 2021
23
Correction for Hutson et al., "Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model". 61
33597175 2021
24
"An epoch-making and blessed moment in the history of medicine" -thoughts on international health equity and the Nobel prize in medicine. 61
33568125 2021
25
A class of viral inducer of degradation of the necroptosis adaptor RIPK3 regulates virus-induced inflammation. 61
33444549 2021
26
MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease. 61
33442693 2021
27
A novel and sensitive real-time PCR system for universal detection of poxviruses. 61
33469067 2021
28
Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018. 61
33422381 2021
29
[THE VACCINATION CONTROVERSY IN THE JEWISH COMMUNITY IN LONDON IN THE LATE 19TH CENTURY: "NOTHING IS NEW UNDER THE SUN"]. 61
33474878 2021
30
Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge. 61
33398010 2021
31
Smallpox Eradication: African Origin, African Solutions, and Relevance for COVID-19. 61
33534731 2021
32
Triumphs and tribulations of COVID-19 vaccines: Lessons to be learned from smallpox epidemics in the 1700s. 61
33432481 2021
33
James Phipps, first to be vaccinated against smallpox by Edward Jenner. 61
33251953 2021
34
Human ABO Blood Groups and Their Associations with Different Diseases. 61
33564677 2021
35
Interleukin 35 Regulatory B Cells. 61
32755620 2021
36
Future threat from the past. 61
33068243 2021
37
A quantitative LC-MS/MS method for the determination of tissue brincidofovir and cidofovir diphosphate in a MuPyV-infected mouse model. 61
33398885 2021
38
Arnold Theiler and colleagues: a -successful cooperation between -Switzerland and South Africa. 61
33528367 2021
39
Superspreaders: A Lurking Danger in the Community. 61
33448254 2021
40
Future perspectives on swine viral vaccines: where are we headed? 61
33397477 2021
41
There are no in-principle ethical objections to controlled voluntary SARS-CoV-2 infection. 61
33393089 2021
42
Orthopoxvirus K3 orthologs show virus- and host-specific inhibition of the antiviral protein kinase PKR. 61
33444388 2021
43
Subversion of Programed Cell Death by Poxviruses. 61
33507400 2021
44
The Joseon-Qing Relations and the King's Health Problems in the Late Joseon Dynasty -Conflict surrounding ritual of greeting envoys in the early reign of King Sukjong. 61
33503647 2020
45
Non-Pharmaceutical Interventions and Military Hygiene at the United States Military Academy between 1890 and 1910. 61
32870979 2020
46
Response to Brinkmann et al. "Re-assembly of 19th century smallpox vaccine genomes reveals the contemporaneous use of horsepox and horsepox-related viruses in the United States". 61
33272282 2020
47
Estimation of Absolute Bioavailability of the Chemical Substance of the Anti-Smallpox Preparation NIOCH-14 in Mice. 61
33263846 2020
48
From inoculation to vaccination: the fight against smallpox in Siena in the 18th and 19th centuries. 61
33257641 2020
49
A multi-pronged scoping review approach to understanding the evolving implementation of the Smallpox and Polio eradication programs: what can other Global Health initiatives learn? 61
33339517 2020
50
Re-assembly of nineteenth-century smallpox vaccine genomes reveals the contemporaneous use of horsepox and horsepox-related viruses in the USA. 61
33272280 2020

Variations for Smallpox

Expression for Smallpox

Search GEO for disease gene expression data for Smallpox.

Pathways for Smallpox

Pathways related to Smallpox according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF IRF1 IL4 IL2 IL1B IL18R1
2
Show member pathways
13.92 TNF IL4 IL2 IL1B IL18R1 IL18
3
Show member pathways
13.78 TNF IL4 IL2 IL1B IL18R1 IL18
4
Show member pathways
13.64 TNF IRF1 IL4 IL2 IL1B IL18R1
5
Show member pathways
13.5 TNF IL4 IL2 IL1B IL18R1 IL18
6
Show member pathways
13.38 TNF IL4 IL2 IL1B IL18R1 IL18
7
Show member pathways
13.33 TNF IRF1 IL4 IL2 IL1B IL18R1
8
Show member pathways
12.97 TNF IL4 IL2 IL1B IFNG ICAM1
9
Show member pathways
12.91 TNF IL2 IL1B IL18 IFNG ICAM1
10
Show member pathways
12.82 TNF IRF1 IL1B IL18R1 IL18BP IL18
11
Show member pathways
12.78 TNF IL4 IL2 IL18R1 IL18 IL12RB2
12
Show member pathways
12.73 TNF IL2 IL1B IL18R1 IL18 IFNG
13
Show member pathways
12.72 TNF IL4 IL2 IL1B IFNG CSF2
14
Show member pathways
12.71 TNF IL4 IL2 IL1B IL18R1 IL18
15
Show member pathways
12.64 TNF IL4 IL2 IFNG ICAM1 GZMB
16 12.64 TNF IRF1 IL4 IL2 IL1B IFNG
17
Show member pathways
12.56 IL4 IL2 IL12RB2 IFNG CSF3 CSF2
18
Show member pathways
12.48 TNF IL4 IL1B IFNG CSF3 CSF2
19
Show member pathways
12.48 TNF IL2 IL18R1 IL18 CXCR3 CXCL9
20
Show member pathways
12.46 TNF MTHFR IL4 IL2 IL1B IFNG
21 12.44 TNF IL1B IL18 CSF2
22
Show member pathways
12.41 TNF IRF1 IL4 IL2 IL1B IL18
23 12.39 TNF IL2 ICAM1 CSF2
24
Show member pathways
12.35 TNF IRF1 IL1B IFNG
25
Show member pathways
12.32 TNF IL4 IL1B IFNG
26
Show member pathways
12.31 TNF IRF1 IL4 IL1B IFNG
27 12.29 TNF IL1B IL18 IFNG
28
Show member pathways
12.27 TNF IRF1 IL2 IL1B
29 12.17 TNF IL1B IFNG ICAM1
30 12.16 TNF IL2 IL1B IL18
31 12.16 TNF IL4 IL2 IL1B IFNG ICAM1
32 12.14 TNF IL4 IL2 IFNG CSF3 CSF2
33 12.13 TNF IL4 IL1B IL18 ICAM1
34 12.12 TNF IRF1 IL1B IL18R1 ICAM1 CSF2
35 12.07 TNF IL4 IL1B CSF3 CSF2
36 12.03 TNF IL1B IFNG CSF2
37 11.98 TNF IL1B IL18 IFNG ICAM1 CSF2
38
Show member pathways
11.97 IL4 IL1B IFNG GZMB
39
Show member pathways
11.92 IRF1 IL1B IFNG
40
Show member pathways
11.92 TNF IL4 IL2 IFNG CSF2
41 11.9 TNF IL2 IL1B IFNG CSF2
42 11.89 IRF1 IL4 IL2 IFNG ICAM1 CSF2
43 11.81 TNF IL4 IL1B CSF3 CSF2
44 11.8 TNF IRF1 IL1B
45
Show member pathways
11.78 TNF IL2 IFNG GZMB
46
Show member pathways
11.75 TNF IL2 IL1B IL18R1 IL18 IL12RB2
47 11.74 IRF1 IL2 IFNG
48 11.74 TNF IL4 ICAM1
49
Show member pathways
11.73 TNF IL2 IL1B IFNG ICAM1 CSF2
50 11.67 TNF IL1B IL18

GO Terms for Smallpox

Cellular components related to Smallpox according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 TNF IL4 IL2 IL1B IL18BP IL18
2 external side of plasma membrane GO:0009897 9.65 TNF IL12RB2 ICAM1 CXCR3 CXCL9
3 extracellular region GO:0005576 9.44 TNF ITIH4 IL4 IL2 IL1B IL18BP
4 immunological synapse GO:0001772 9.33 ICAM1 GZMB GZMA

Biological processes related to Smallpox according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 TNF IRF1 IL4 IL2 IL18 CXCR3
2 apoptotic process GO:0006915 10.14 IRF1 IL1B IFNG GZMB GZMA CXCR3
3 positive regulation of gene expression GO:0010628 10.07 TNF IL4 IL1B IL18 IFNG CSF2
4 inflammatory response GO:0006954 10.03 TNF IL1B IL18R1 IL18 CXCR3 CXCL9
5 positive regulation of cell proliferation GO:0008284 10.01 IL4 IL2 IL1B IL12RB2 IFNG CXCR3
6 cell-cell signaling GO:0007267 10 IL2 IL1B IL18 CXCL9
7 MAPK cascade GO:0000165 10 TNF IL2 IL1B IL18 CSF2
8 positive regulation of protein phosphorylation GO:0001934 9.98 TNF IL2 IL1B IFNG
9 response to lipopolysaccharide GO:0032496 9.96 IL1B IL18BP IL12RB2 ICAM1
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.92 TNF IL1B IL18R1 IL18 ICAM1
11 regulation of insulin secretion GO:0050796 9.87 TNF IL1B IFNG
12 interferon-gamma-mediated signaling pathway GO:0060333 9.87 IRF1 IFNG ICAM1
13 cellular response to organic cyclic compound GO:0071407 9.86 TNF IL1B IL18
14 positive regulation of T cell proliferation GO:0042102 9.86 IL4 IL2 IL1B
15 cellular response to cytokine stimulus GO:0071345 9.85 IL18R1 IL18BP CSF3
16 positive regulation of inflammatory response GO:0050729 9.85 TNF IL2 IL1B IL18 IFNG
17 cellular response to lipopolysaccharide GO:0071222 9.85 TNF IL1B ICAM1 CXCL9 CSF3 CSF2
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.84 TNF IL1B IL18R1 IL18
19 positive regulation of phagocytosis GO:0050766 9.8 TNF IL1B IFNG
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 TNF IL1B IFNG ICAM1
21 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.79 TNF IL1B CSF2
22 lipopolysaccharide-mediated signaling pathway GO:0031663 9.79 TNF IL1B IL18
23 microglial cell activation GO:0001774 9.77 TNF IL4 IFNG
24 natural killer cell activation GO:0030101 9.74 IL2 IL18R1 IL18
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 TNF IL4 IL2 IL18 IFNG CSF2
26 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 TNF IL1B IFNG
27 negative regulation of amyloid-beta clearance GO:1900222 9.71 TNF IFNG
28 positive regulation of podosome assembly GO:0071803 9.71 TNF CSF2
29 positive regulation of MHC class II biosynthetic process GO:0045348 9.71 IL4 IFNG
30 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B
31 T-helper 1 type immune response GO:0042088 9.7 IL18BP IL18
32 negative regulation of T-helper 17 cell differentiation GO:2000320 9.69 IL4 IL2
33 positive regulation of isotype switching to IgG isotypes GO:0048304 9.69 IL4 IL2
34 positive regulation of neuroinflammatory response GO:0150078 9.69 TNF IL1B IL18
35 vascular endothelial growth factor production GO:0010573 9.67 TNF IL1B
36 positive regulation of mononuclear cell migration GO:0071677 9.67 TNF IL4
37 positive regulation of tissue remodeling GO:0034105 9.66 IL2 IL18
38 positive regulation of cellular respiration GO:1901857 9.65 IL4 IFNG
39 neuroinflammatory response GO:0150076 9.65 IL4 IFNG
40 interleukin-18-mediated signaling pathway GO:0035655 9.65 IL18R1 IL18BP IL18
41 type 2 immune response GO:0042092 9.64 IL4 IL18
42 positive regulation of interleukin-23 production GO:0032747 9.64 IFNG CSF2
43 positive regulation of fever generation GO:0031622 9.63 TNF IL1B
44 positive regulation of interferon-gamma production GO:0032729 9.63 TNF IL2 IL1B IL18R1 IL18 IL12RB2
45 sequestering of triglyceride GO:0030730 9.62 TNF IL1B
46 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.61 IL1B IL18R1 IL18
47 cytokine-mediated signaling pathway GO:0019221 9.61 TNF IL4 IL2 IL1B IL18 IL12RB2
48 positive regulation of vitamin D biosynthetic process GO:0060557 9.58 TNF IFNG
49 positive regulation of nitrogen compound metabolic process GO:0051173 9.58 TNF IFNG
50 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.5 TNF IL1B IFNG

Molecular functions related to Smallpox according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL4 IL2 CSF3 CSF2
2 cytokine activity GO:0005125 9.28 TNF IL4 IL2 IL1B IL18 IFNG
3 interleukin-18 binding GO:0042007 8.96 IL18R1 IL18BP

Sources for Smallpox

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....